NEW YORK (GenomeWeb News) – Helicos BioSciences said after the close of the market yesterday that it has priced a registered direct offering of 6.4 million units at $1 per unit, which would provide the firm with $6.4 million in gross proceeds.

Each unit in the offering consists of one share of Helicos common stock and a warrant to buy .65 of a share of common stock. The warrants are exercisable for a period of five years beginning six months after issuance, at an exercise price of $1.4385 per share.

Helicos expects to close the offering on or around Dec. 21.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: locus linked to non-syndromic hearing loss, phylogenetic relationships of Klebsiella pneumoniae isolates, and more.

In a column at Nature, researcher Fyodor Kondrashov worries about the influence of politics on Russian science.

The term 'epigenetics' is being used by quacks to give them a veneer of science, writes Adam Rutherford at the Observer.

The NIH has issued a preliminary guidance for newborn dried blood spot research.